Literature DB >> 18347889

Staphylococcus aureus nasal decolonization in joint replacement surgery reduces infection.

Donna M Hacek1, William J Robb, Suzanne M Paule, James C Kudrna, Van Paul Stamos, Lance R Peterson.   

Abstract

UNLABELLED: Surgical site infections (SSIs) with Staphylococcus aureus are a recognized adverse event of hip and knee replacements. We evaluated the impact of a program to detect S. aureus nasal carriers before surgery with preoperative decolonization (using mupirocin twice daily for 5 days prior to surgery) of carriers. Nasal swab samples were obtained from patients prior to surgery from 8/1/2003 through 2/28/2005. Samples were tested using real-time PCR technology to detect S. aureus. The group that developed S. aureus SSI was compared to a combined concurrent and historical control for one year following the operation. S. aureus caused 71% of SSIs in the combined control groups. Of the 1495 surgical candidates evaluated, 912 (61.0%) were screened for S. aureus; 223 of those screened (24.5%) were positive and then decolonized with mupirocin. Among the 223 positive and decolonized patients, three (1.3%) developed a SSI. Among the 689 screen-negative patients, four (0.6%) developed SSIs for an overall rate of 0.77%. Among the 583 control patients who were not screened or decolonized, 10 (1.7%) developed S. aureus SSIs. SSIs from other organisms were 0.44% and 0.69%, respectively. LEVEL OF EVIDENCE: Level III, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347889      PMCID: PMC2384050          DOI: 10.1007/s11999-008-0210-y

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  17 in total

1.  Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery.

Authors:  M D Kalmeijer; E van Nieuwland-Bollen; D Bogaers-Hofman; G A de Baere
Journal:  Infect Control Hosp Epidemiol       Date:  2000-05       Impact factor: 3.254

2.  Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus.

Authors:  J A Kluytmans; J W Mouton; M F VandenBergh; M J Manders; A P Maat; J H Wagenvoort; M F Michel; H A Verbrugh
Journal:  Infect Control Hosp Epidemiol       Date:  1996-12       Impact factor: 3.254

3.  Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics.

Authors:  G E Cimochowski; M D Harostock; R Brown; M Bernardi; N Alonzo; K Coyle
Journal:  Ann Thorac Surg       Date:  2001-05       Impact factor: 4.330

4.  Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study.

Authors:  M D Kalmeijer; H Coertjens; P M van Nieuwland-Bollen; D Bogaers-Hofman; G A J de Baere; A Stuurman; A van Belkum; J A J W Kluytmans
Journal:  Clin Infect Dis       Date:  2002-07-15       Impact factor: 9.079

5.  Use of perioperative mupirocin to prevent methicillin-resistant Staphylococcus aureus (MRSA) orthopaedic surgical site infections.

Authors:  M H Wilcox; J Hall; H Pike; P A Templeton; W N Fawley; P Parnell; P Verity
Journal:  J Hosp Infect       Date:  2003-07       Impact factor: 3.926

6.  Direct detection of Staphylococcus aureus from adult and neonate nasal swab specimens using real-time polymerase chain reaction.

Authors:  Suzanne M Paule; Anna C Pasquariello; Donna M Hacek; Adrienne G Fisher; Richard B Thomson; Karen L Kaul; Lance R Peterson
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

7.  Budget impact analysis of rapid screening for Staphylococcus aureus colonization among patients undergoing elective surgery in US hospitals .

Authors:  Gary A Noskin; Robert J Rubin; Jerome J Schentag; Jan Kluytmans; Edwin C Hedblom; Cassie Jacobson; Maartje Smulders; Eric Gemmen; Murtuza Bharmal
Journal:  Infect Control Hosp Epidemiol       Date:  2008-01       Impact factor: 3.254

8.  Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus.

Authors:  Deverick J Anderson; Daniel J Sexton; Zeina A Kanafani; Grace Auten; Keith S Kaye
Journal:  Infect Control Hosp Epidemiol       Date:  2007-07-12       Impact factor: 3.254

9.  Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections.

Authors:  Trish M Perl; Joseph J Cullen; Richard P Wenzel; M Bridget Zimmerman; Michael A Pfaller; Deborah Sheppard; Jennifer Twombley; Pamela P French; Loreen A Herwaldt
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

10.  Reference group choice and antibiotic resistance outcomes.

Authors:  Keith S Kaye; John J Engemann; Essy Mozaffari; Yehuda Carmeli
Journal:  Emerg Infect Dis       Date:  2004-06       Impact factor: 6.883

View more
  31 in total

1.  The economic effect of screening orthopedic surgery patients preoperatively for methicillin-resistant Staphylococcus aureus.

Authors:  Bruce Y Lee; Ann E Wiringa; Rachel R Bailey; Vishal Goyal; Becky Tsui; G Jonathan Lewis; Robert R Muder; Lee H Harrison; Lee M Harrison
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

2.  Microbiological aetiology, epidemiology, and clinical profile of prosthetic joint infections: are current antibiotic prophylaxis guidelines effective?

Authors:  Trisha N Peel; Allen C Cheng; Kirsty L Buising; Peter F M Choong
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

3.  Nasal Carriage of Epidemic Methicillin-Resistant Staphylococcus aureus 15 (EMRSA-15) Clone Observed in Three Chicago-Area Long-Term Care Facilities.

Authors:  Sanchita Das; Christopher J Anderson; Althea Grayes; Katherine Mendoza; Maureen Harazin; Donna M Schora; Lance R Peterson
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

4.  The Otto Aufranc Award: Modifiable versus nonmodifiable risk factors for infection after hip arthroplasty.

Authors:  Guy Maoz; Michael Phillips; Joseph Bosco; James Slover; Anna Stachel; Ifeoma Inneh; Richard Iorio
Journal:  Clin Orthop Relat Res       Date:  2015-02       Impact factor: 4.176

5.  Editor's Spotlight/Take 5: Addition of Vancomycin to Cefazolin Prophylaxis Is Associated With Acute Kidney Injury After Primary Joint Arthroplasty.

Authors:  M Daniel Wongworawat
Journal:  Clin Orthop Relat Res       Date:  2015-04-25       Impact factor: 4.176

6.  Prevention of surgical site infections in bone and joint procedures.

Authors:  Ralf-Peter Vonberg; Petra Gastmeier
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

7.  Twenty Percent of Patients May Remain Colonized With Methicillin-resistant Staphylococcus aureus Despite a Decolonization Protocol in Patients Undergoing Elective Total Joint Arthroplasty.

Authors:  Michael D Baratz; Ruth Hallmark; Susan M Odum; Bryan D Springer
Journal:  Clin Orthop Relat Res       Date:  2015-07       Impact factor: 4.176

8.  Optimization of a laboratory-developed test utilizing roche analyte-specific reagents for detection of Staphylococcus aureus, methicillin-resistant S. aureus, and vancomycin-resistant Enterococcus species.

Authors:  Maitry S Mehta; Suzanne M Paule; Donna M Hacek; Richard B Thomson; Karen L Kaul; Lance R Peterson
Journal:  J Clin Microbiol       Date:  2008-04-30       Impact factor: 5.948

9.  A Guide to Improving the Care of Patients with Fragility Fractures, Edition 2.

Authors:  Simon C Mears; Stephen L Kates
Journal:  Geriatr Orthop Surg Rehabil       Date:  2015-06

10.  Nonimpact of Decolonization as an Adjunctive Measure to Contact Precautions for the Control of Methicillin-Resistant Staphylococcus aureus Transmission in Acute Care.

Authors:  Lance R Peterson; Marc O Wright; Jennifer L Beaumont; Vanida Komutanon; Parul A Patel; Donna M Schora; Bryan H Schmitt; Ari Robicsek
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.